Hexavalent anti capsular polysaccharide
Vaccineexperimental
Clinical trial activity
1 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Oct 14, 2022 (NCT05832502)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- EotaxinImmunity, active
CCL11 immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05832502 | Phase 2 | Oct 14, 2022 | Johns Hopkins University, Pfizer, University of London |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Johns Hopkins University | Academic/Hospital | 1 | 0 | 1 | 2022 |
| Pfizer | For profit | 1 | 0 | 1 | 2022 |
| University of London | Academic/Hospital | 1 | 1 | 1 | 2022 |
3 organizations
Page 1 / 1